Navigation Links
Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Date:9/2/2008

c journals -- Circulation and the Journal of Thrombosis and Haemostasis.

Regado is currently evaluating REG1 in 26 patients undergoing elective percutaneous coronary intervention (PCI). The multi-center, open-label, randomized Phase IIa study designated REVERSAL-PCI will assess whether REG1 can replace standard heparin therapy during the performance of PCI with stenting.

REG1 is the first specific, direct-acting anticoagulant controllable by its matched reversal agent. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), put patients at a high risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures. Intellectual property covering this technology derives from work originating in Duke University Medical Center's Division of Surgical Sciences, which was not involved in the subsequent clinical studies. Duke exclusively licensed the technology to Regado and will receive certain payments from Regado under this license.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched reversal agent. The REG1 anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits factor IXa, a protein that is critical to blood coagulation. The reversal agent, RB007, is a complementary nucleic acid that binds to and neutralizes RB006. The amount of RB007 administered allows physicians to fine tune the pharmacodynamic effect of RB006, from slight reduction in anticoagulation all the way to complete reversal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of two-c
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... , Sept. 1, 2014 Reportbuyer.com has ... Brazil Aesthetic Lasers and Energy Devices Market ... https://www.reportbuyer.com/product/2343455/Brazil-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Brazil Aesthetic Lasers and ... Summary GlobalData,s new report, "Brazil ... 2020", provides key market data on the Brazil ...
(Date:9/1/2014)... 2014 Reportlinker.com announces ... in its catalogue: Antibody Drug Conjugates ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION ... of therapeutic agents, gaining increasing attention from both ... the marriage of an antibody with a toxic ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue:  Drug Discovery Technologies - A Global ... The development of new drugs ... extensive expenditure, in addition to consuming a lot ... new drug involves the utilizing high-throughput screening of ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... GOLDEN, Colo., Nov. 9 ABR-Affinity,BioReagents, a leading ... again exhibit at Medica in Dusseldorf, Germany. ... with over 137,000,visitors expected from all parts of ... BioReagents. The exposure is global, and it is ...
... Nov. 9 This week, Dr. Fouad,Bachour, ... Hennepin County,Medical Center, presented results of a ... http://www.sessionsdailynews.com/tuesday.pdf ) meeting in Orlando showing,that alerting ... a heart attack,patient arrives improves door-to-balloon times ...
Cached Medicine Technology:ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 ... two American aid workers successfully cured a group of monkeys ... The drug, ZMapp, prompted recovery in all 18 monkeys ... until five days after infection. ZMapp even cured monkeys ... hours away from death, said study senior author Gary Kobinger, ...
(Date:9/1/2014)... Denham Springs, LA (PRWEB) September 01, 2014 ... Crisis Intervention Instructor training, Derek is currently pursuing counselor ... been able to advance through the CPI training program ... Derek states "and I have grown both personally and ... addicts permanently recover, I am competently able to do ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
(Date:9/1/2014)... NJ (PRWEB) September 01, 2014 Registration is ... The Warriors® 5K and 1-Mile Race to be held on ... The Plaza Court Yard at Harmon Meadow in Secaucus, New ... The Warriors®, a national nonprofit dedicated to restoring a sense ... our service members and our military families. , General registration ...
Breaking Medicine News(10 mins):Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... New data is showing a dramatic,reduction in ... this country.,Here,s more on one group,s 20-year effort ... this report from Safe Kids Worldwide at:, http://media.medialink.com/WebNR.aspx?story=35058 ... text, graphics and,photos for free and unrestricted use ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... finds antidepressant cut inflammation in relapsing remitting illness ... help reduce disease activity in people with the relapsing ... suggests. , Forty patients with the disease were randomly ... fluoxetine (Prozac) or a placebo for 24 weeks. MRI ...
... SAN DIEGO, April 30 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... will release its,first quarter financial results before the ... management will host a conference call and live ...
... Treatment Approved to Both Reduce Exacerbations ... and Improve ... The,U.S. Food and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone ... reduction of exacerbations in patients with chronic obstructive,pulmonary disease (COPD) ...
... on Children,s Physical Activity in Child Care Focuses on Child Care ... ... Annual Meeting, CINCINNATI, April 30 At ... care centers, and growing concern over,childhood obesity has led physicians to focus ...
Cached Medicine News:Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2Health News:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 2Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 3Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 4
... is,a no-extraction, solid-phase 125I,radioimmunoassay ... use in the quantitative,measurement ... for the,differential diagnosis of ... ovulation induction with,and without ...
... Generation Estradiol EIA is intended ... Estradiol measurements are used in ... various hormonal sexual disorders and ... complicated pregnancy. This assay is ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
... high-throughput immunoassay system built around the many ... the important addition of Logic Driven Incubation ... designed for optimal performance with the fastest ... assays such as the cardiac biomarkers and ...
Medicine Products: